TNFRSF17 and Miyoshi myopathy: Importantly, follow-up assessments one week after the final fourth treatment revealed no evidence of recurrence or tumor regrowth in this cohort, demonstrating the treatment's ability to effectively eliminate BCMA-positive MM cells and prevent relapse (Figure 4B).